FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069380317> ?p ?o ?g. }

• W2069380317 endingPage "1496" @default.
• W2069380317 startingPage "1486" @default.
• W2069380317 abstract "To identify the determinants of antibody responses to adjuvanted split influenza A (H1N1) vaccines in patients with inflammatory rheumatic diseases.One hundred seventy-three patients (82 with rheumatoid arthritis, 45 with spondylarthritis, and 46 with other inflammatory rheumatic diseases) and 138 control subjects were enrolled in this prospective single-center study. Controls received 1 dose of adjuvanted influenza A/09/H1N1 vaccine, and patients received 2 doses of the vaccine. Antibody responses were measured by hemagglutination inhibition assay before and 3-4 weeks after each dose. Geometric mean titers (GMTs) and rates of seroprotection (GMT≥40) were calculated. A comprehensive medical questionnaire was used to identify the determinants of vaccine responses and adverse events.Baseline influenza A/09/H1N1 antibody levels were low in patients and controls (seroprotection rates 14.8% and 14.2%, respectively). A significant response to dose 1 was observed in both groups. However, the GMT and the seroprotection rate remained significantly lower in patients (GMT 146 versus 340, seroprotection rate 74.6% versus 87%; both P<0.001). The second dose markedly increased antibody titers in patients, with achievement of a similar GMT and seroprotection rate as elicited with a single dose in healthy controls. By multivariate regression analysis, increasing age, use of disease-modifying antirheumatic drugs (DMARDs) (except hydroxychloroquine and sulfasalazine), and recent (within 3 months) B cell depletion treatment were identified as the main determinants of vaccine responses; tumor necrosis factor α antagonist treatment was not identified as a major determinant. Immunization was well tolerated, without any adverse effect on disease activity.DMARDs exert distinct influences on influenza vaccine responses in patients with inflammatory rheumatic diseases. Two doses of adjuvanted vaccine were necessary and sufficient to elicit responses in patients similar to those achieved with 1 dose in healthy controls." @default.
• W2069380317 created "2016-06-24" @default.
• W2069380317 creator A5005416098 @default.
• W2069380317 creator A5013896104 @default.
• W2069380317 creator A5021089252 @default.
• W2069380317 creator A5024739919 @default.
• W2069380317 creator A5030631117 @default.
• W2069380317 creator A5057895302 @default.
• W2069380317 creator A5059758535 @default.
• W2069380317 creator A5061159661 @default.
• W2069380317 creator A5064865817 @default.
• W2069380317 creator A5070508417 @default.
• W2069380317 creator A5070691482 @default.
• W2069380317 creator A5082324244 @default.
• W2069380317 date "2011-05-31" @default.
• W2069380317 modified "2023-10-16" @default.
• W2069380317 title "Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study" @default.
• W2069380317 cites W1968498984 @default.
• W2069380317 cites W1973258283 @default.
• W2069380317 cites W1974114500 @default.
• W2069380317 cites W1974559223 @default.
• W2069380317 cites W1977889566 @default.
• W2069380317 cites W1985004174 @default.
• W2069380317 cites W1998170980 @default.
• W2069380317 cites W1998618256 @default.
• W2069380317 cites W2021481766 @default.
• W2069380317 cites W2027502756 @default.
• W2069380317 cites W2037976962 @default.
• W2069380317 cites W2039077567 @default.
• W2069380317 cites W2046235380 @default.
• W2069380317 cites W2052906913 @default.
• W2069380317 cites W2056808954 @default.
• W2069380317 cites W2059903231 @default.
• W2069380317 cites W2064999867 @default.
• W2069380317 cites W2067104388 @default.
• W2069380317 cites W2081679819 @default.
• W2069380317 cites W2088235366 @default.
• W2069380317 cites W2100779666 @default.
• W2069380317 cites W2110949543 @default.
• W2069380317 cites W2111299679 @default.
• W2069380317 cites W2116458521 @default.
• W2069380317 cites W2118742196 @default.
• W2069380317 cites W2120427700 @default.
• W2069380317 cites W2125291401 @default.
• W2069380317 cites W2127532898 @default.
• W2069380317 cites W2140116237 @default.
• W2069380317 cites W2142239745 @default.
• W2069380317 cites W2146203649 @default.
• W2069380317 cites W2148069290 @default.
• W2069380317 cites W2151165850 @default.
• W2069380317 cites W2152348310 @default.
• W2069380317 cites W2154652582 @default.
• W2069380317 cites W2155957466 @default.
• W2069380317 cites W2157134939 @default.
• W2069380317 cites W2165601272 @default.
• W2069380317 cites W2264075806 @default.
• W2069380317 cites W2264923623 @default.
• W2069380317 cites W4205978945 @default.
• W2069380317 cites W4251323090 @default.
• W2069380317 doi "https://doi.org/10.1002/art.30325" @default.
• W2069380317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21384334" @default.
• W2069380317 hasPublicationYear "2011" @default.
• W2069380317 type Work @default.
• W2069380317 sameAs 2069380317 @default.
• W2069380317 citedByCount "117" @default.
• W2069380317 countsByYear W20693803172012 @default.
• W2069380317 countsByYear W20693803172013 @default.
• W2069380317 countsByYear W20693803172014 @default.
• W2069380317 countsByYear W20693803172015 @default.
• W2069380317 countsByYear W20693803172016 @default.
• W2069380317 countsByYear W20693803172017 @default.
• W2069380317 countsByYear W20693803172018 @default.
• W2069380317 countsByYear W20693803172019 @default.
• W2069380317 countsByYear W20693803172020 @default.
• W2069380317 countsByYear W20693803172021 @default.
• W2069380317 countsByYear W20693803172022 @default.
• W2069380317 countsByYear W20693803172023 @default.
• W2069380317 crossrefType "journal-article" @default.
• W2069380317 hasAuthorship W2069380317A5005416098 @default.
• W2069380317 hasAuthorship W2069380317A5013896104 @default.
• W2069380317 hasAuthorship W2069380317A5021089252 @default.
• W2069380317 hasAuthorship W2069380317A5024739919 @default.
• W2069380317 hasAuthorship W2069380317A5030631117 @default.
• W2069380317 hasAuthorship W2069380317A5057895302 @default.
• W2069380317 hasAuthorship W2069380317A5059758535 @default.
• W2069380317 hasAuthorship W2069380317A5061159661 @default.
• W2069380317 hasAuthorship W2069380317A5064865817 @default.
• W2069380317 hasAuthorship W2069380317A5070508417 @default.
• W2069380317 hasAuthorship W2069380317A5070691482 @default.
• W2069380317 hasAuthorship W2069380317A5082324244 @default.
• W2069380317 hasConcept C126322002 @default.
• W2069380317 hasConcept C159654299 @default.
• W2069380317 hasConcept C188816634 @default.
• W2069380317 hasConcept C197934379 @default.
• W2069380317 hasConcept C203014093 @default.
• W2069380317 hasConcept C22070199 @default.
• W2069380317 hasConcept C22889606 @default.
• W2069380317 hasConcept C2777575956 @default.

• next